DAVIS, Calif.–(BUSINESS WIRE)–Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology
company, today announced that it's achieved two key technology
milestones in its High Fiber Resistant Starch (RS) Wheat program. First,
through advanced screening and traditional breeding techniques, the
company has developed non-transgenic (non-GM) wheat varieties that
contain up to 94 percent amylose, the highest levels available.
Increased levels of amylose correspond to high levels of resistant
starch, which has been proven to deliver significant health benefits.
Second, these same wheat varieties deliver levels of total dietary fiber
high enough to meet the threshold required by the US Food and Drug
Administration for a “Good Source” of fiber or “High in Fiber”
designation on consumer packaging.
“These milestones are key achievements in the commercial launch plan for
our non-GM wheat ingredients portfolio, delivering health benefits to
consumers and distinct market differentiators to consumer packaged goods
companies,” said Raj Ketkar, president and CEO of Arcadia Biosciences.
“Arcadia’s new wheat varieties will allow people to enjoy the foods they
love with the health benefits of resistant starch and dietary fiber,
while satisfying consumer demand for clean-label, natural foods.”
Arcadia is working with a select number of consumer packaged goods
companies on new, healthier formulations of existing products using both
enriched and whole wheat RS Wheat flour. The company is preparing for an
increase in acres planted during the upcoming US wheat growing season.
Resistant starch has many benefits compared to other types of starch,
particularly in the management of gastrointestinal health and
obesity-related health conditions, such as cardiovascular disease and
type 2 diabetes. It contains higher amounts of amylose, a carbohydrate
molecule that's less vulnerable to digestion. Because it's digested
more slowly, resistant starch has a lower glycemic index, meaning it
doesn't cause a rapid increase in blood glucose levels. Resistant
starch also acts as a nondigestible prebiotic that promotes the growth
of “good bacteria” (probiotics) that improve gut health.
Some of the additional reported health benefits of resistant starch
–. Increased absorption of calcium and other key minerals
–. Improved weight loss through increased feeling of satiety
–. Increased insulin sensitivity – helpful for cardiovascular disease,
type 2 diabetes, metabolic syndrome, obesity and Alzheimer’s disease
–. Increased production of butyrate – an anti-inflammatory which may help
burn body fat and recently consumed fat.
In addition to the benefits of resistant starch, Arcadia’s RS Wheat
varieties produce refined flour and whole grain flour that's naturally
high in fiber. Many products marketed as “high fiber” contain fiber
additives, such as inulin, cellulose and psyllium husk. Arcadia’s RS
Wheat has intrinsically high levels of fiber and can enable food
companies to reduce the use of added fiber sources in their formulations
to simplify their ingredient labels.
Wheat flour is a major part of people’s diets on a global level. In
2015, the global wheat flour market was valued at $200 billion and is
estimated to reach a value of $270 billion by 2022. On average, one
quarter. 500 calories, of Americans’ daily caloric intake comes from
wheat. Arcadia’s RS Wheat varieties have the opportunity to provide
additional, proven health benefits for consumers who want to continue to
enjoy the wheat-based foods they love.
About Arcadia Biosciences, Inc.
Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops
agricultural products that create added value for farmers, enhance human
health and improve the environmental sustainability of agriculture.
Arcadia’s nutrition traits and products are aimed at creating healthier
ingredients and whole foods with lower production costs. Arcadia’s
agronomic performance traits are aimed at making agricultural production
more economically efficient and environmentally sound. For more
information, visit www.arcadiabio.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the company’s wheat traits and the
commercialization of these traits. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to
differ materially. Reported results shouldn't be considered as an
indication of future performance. These risks and uncertainties include,
but aren't limited to: the company’s and its partners’ and affiliates’
ability to identify and isolate desired traits. The company’s and its
partners’ ability to develop commercial products incorporating its
traits and complete the regulatory review process for such products. The
company’s compliance with laws and regulations that impact the company’s
business. Changes to such laws and regulations. The company’s future
capital requirements and ability to satisfy its capital needs. The
other risks set forth in the company’s filings with the Securities and
Exchange Commission from time to time, including the risks set forth in
the company’s Annual Report on Form 10-K for the year ended December 31,
2016. These forward-looking statements speak only as of the date hereof,
and Arcadia Biosciences, Inc. disclaims any obligation to update these
Arcadia Biosciences, Inc.